These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1145 related articles for article (PubMed ID: 11654274)

  • 41. Multicenter trials and subject eligibility: should local IRBs play a role?
    Freedman B
    IRB; 1994; 16(1-2):1-6. PubMed ID: 11652320
    [No Abstract]   [Full Text] [Related]  

  • 42. The paradoxical case of payment as benefit to research subjects.
    Macklin R
    IRB; 1989; 11(6):1-3. PubMed ID: 11650284
    [No Abstract]   [Full Text] [Related]  

  • 43. Federal agency's final rule says informed consent forms must be dated.
    Maloney DM
    Hum Res Rep; 1996 Dec; 11(12):1-2. PubMed ID: 11655034
    [No Abstract]   [Full Text] [Related]  

  • 44. The Food and Drug Administration's role in the protection of human subjects.
    Nightingale SL
    IRB; 1983; 5(1):6-9. PubMed ID: 11649511
    [No Abstract]   [Full Text] [Related]  

  • 45. Minutes of meeting, 30-31 May 1991.
    U.S. National Institutes of Health. Recombinant DNA Advisory Committee
    Hum Gene Ther; 1992 Feb; 3(1):95-121. PubMed ID: 11642989
    [No Abstract]   [Full Text] [Related]  

  • 46. Federal report says protection of human subjects is threatened by numerous factors.
    Maloney DM
    Hum Res Rep; 1996 May; 11(5):1-3. PubMed ID: 11654438
    [No Abstract]   [Full Text] [Related]  

  • 47. Research compliance changes will affect rules on protection of human subjects.
    Maloney DM
    Hum Res Rep; 1999 May; 14(5):1-2. PubMed ID: 11657776
    [No Abstract]   [Full Text] [Related]  

  • 48. National Institutes of Health. Points to consider in the design and submission of human somatic-cell gene therapy protocols. Human Gene Therapy Subcommittee, NIH Recombinant DNA Advisory Committee. Adopted September 29, 1986.
    Recomb DNA Tech Bull; 1986 Dec; 9(4):221-42. PubMed ID: 3469693
    [No Abstract]   [Full Text] [Related]  

  • 49. Half-full or half-empty? Evaluating IRB performance.
    Mishkin B; Ariand N
    Prof Ethics Rep; 1998; 11(3):4-7. PubMed ID: 11657925
    [No Abstract]   [Full Text] [Related]  

  • 50. Neurobiological research involving human subjects: perspectives from the Office for Protection from Research Risks.
    Puglisi JT; Ellis GB
    Account Res; 1996; 4(3-4):261-5. PubMed ID: 11654521
    [No Abstract]   [Full Text] [Related]  

  • 51. HEW proposed policy on the protection of human subjects: experimentation and the institutionalized mentally disabled.
    Wash Univ Law Q; 1975; 1975(3):745-74. PubMed ID: 11662989
    [No Abstract]   [Full Text] [Related]  

  • 52. The IRB's role in assessing the generalizability of non-NIH-funded clinical trials.
    Weijer C
    IRB; 1998; 20(2-3):1-5. PubMed ID: 11656912
    [No Abstract]   [Full Text] [Related]  

  • 53. Government regulation of human gene therapy.
    Gage JL
    Jurimetrics; 1987; 27(2):200-18. PubMed ID: 11651978
    [No Abstract]   [Full Text] [Related]  

  • 54. Using the brain dead for medical research.
    Martyn SR
    Utah Law Rev; 1986; 1986(1):1-28. PubMed ID: 11651917
    [No Abstract]   [Full Text] [Related]  

  • 55. Gene therapy in mental retardation: ethical considerations.
    Fletcher JC
    Ment Retard Dev Disabil Res Rev; 1995; 1():7-13. PubMed ID: 11660293
    [No Abstract]   [Full Text] [Related]  

  • 56. OPRR and FDA propose revised expedited review categories.
    McGough H
    IRB; 1998; 20(1):9, 11. PubMed ID: 11655326
    [No Abstract]   [Full Text] [Related]  

  • 57. Recombinant DNA research: notice of intent to propose amendments to the NIH Guidelines for research involving recombinant DNA molecules (NIH Guidelines) regarding enhanced mechanisms for NIH oversight of recombinant DNA activities.
    U.S. National Institutes of Health
    Fed Regist; 1996 Jul; 61(131):35774-7. PubMed ID: 11654428
    [No Abstract]   [Full Text] [Related]  

  • 58. Trends in gene therapy regulation.
    Lecomte V; Taylor A
    Gene Ther; 1997 Feb; 4(2):77-8. PubMed ID: 11644906
    [No Abstract]   [Full Text] [Related]  

  • 59. Report says institutional review boards are conducting inadequate reviews.
    Maloney DM
    Hum Res Rep; 1998 Sep; 13(9):1-2. PubMed ID: 11660603
    [No Abstract]   [Full Text] [Related]  

  • 60. Obtaining "informed consent": controversy over radiation tests focuses attention on rules for human subjects.
    Wheeler DL
    Chron High Educ; 1994 Jan; 40():8-9, 16. PubMed ID: 11658067
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.